- AU$872.73m
- AU$941.36m
- $7.50m
- 27
- 43
- 61
- 42
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.12 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 76.4 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -8.59% | ||
| Return on Equity | -14.49% | ||
| Operating Margin | -735.47% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 16.72 | 32.16 | 7.46 | 10.21 | 7.5 | 6.41 | 11.03 | -15.43% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mesoblast Limited is an Australia-based is developing a range of late-stage product candidates derived from its proprietary mesenchymal lineage cell therapy technology platforms. The Company’s Remestemcel-L is mesenchymal lineage stromal cell product platform and is in late-stage development for treatment of systemic inflammatory diseases, including Pediatric steroid refractory acute Graft versus Host Disease (SR-aGVHD), acute respiratory distress syndrome (ARDS) and Biologic refractory inflammatory bowel disease. Its Rexlemestrocel-L is mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of advanced chronic heart failure (CHF) and chronic low back pain (CLBP) due to degenerative disc disease. Two products are commercialized in Japan and Europe by the Company’s licensees, and it has a commercial partnership in Europe and China for certain Phase III assets.
Directors
- Joseph Swedish NEC (69)
- Silviu Itescu CEO
- William Burns VCH (73)
- Andrew Chaponnel CFO
- Dagmar Rosa - Bjorkeson COO (57)
- Peter Howard GCN
- Justin Horst OTH
- Michael Schuster OTH
- Paul Simmons OTH
- Geraldine Storton OTH
- Eric Rose NED (70)
- Philip Facchina NID (57)
- Donal O'Dwyer NID (68)
- Michael Spooner NID
- Shawn Tomasello NID (62)
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- June 8th, 2004
- Public Since
- December 16th, 2004
- No. of Shareholders
- 34,816
- No. of Employees
- 83
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 1,014,799,334
- Address
- L 38 55 Collins St, MELBOURNE, 3000
- Web
- https://www.mesoblast.com/
- Phone
- +61 396396036
- Auditors
- PricewaterhouseCoopers
Upcoming Events for MSB
Similar to MSB
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Mesoblast share price?
As of Today at 19:14 UTC, shares in Mesoblast are trading at AU$0.86. This share price information is delayed by 15 minutes.
How has the Mesoblast share price performed this year?
Shares in Mesoblast last closed at AU$0.86 and the price had moved by -11.79% over the past 365 days. In terms of relative price strength the Mesoblast share price has underperformed the ASX All Ordinaries Index by -17.84% over the past year.
What are the analyst and broker recommendations for Mesoblast?
The overall consensus recommendation for Mesoblast is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Mesoblast dividend yield?
Mesoblast does not currently pay a dividend.
Does Mesoblast pay a dividend?
Mesoblast does not currently pay a dividend.
When does Mesoblast next pay dividends?
Mesoblast does not currently pay a dividend.
How do I buy Mesoblast shares?
To buy shares in Mesoblast you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mesoblast?
As of the previous close price of AU$0.86, shares in Mesoblast had a market capitalisation of AU$872.73m.
Where are Mesoblast shares listed?
Here are the trading details for Mesoblast:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: MSB
What kind of share is Mesoblast?
Based on an overall assessment of its quality, value and momentum Mesoblast is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mesoblast share price forecast for 2024?
The analyst consensus target price for shares in Mesoblast is AU$1.61. That is 86.8% above the last closing price of AU$0.86.
Analysts covering Mesoblast currently have a consensus Earnings Per Share (EPS) forecast of -$0.39 for the next financial year.
What is the trend in the Mesoblast share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mesoblast. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +110.53%.
As of the last closing price of AU$0.86, shares in Mesoblast were trading +75.06% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mesoblast PE Ratio?
The Mesoblast PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.86.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mesoblast?
Mesoblast's management team is headed by:
- Joseph Swedish - NEC
- Silviu Itescu - CEO
- William Burns - VCH
- Andrew Chaponnel - CFO
- Dagmar Rosa - Bjorkeson - COO
- Peter Howard - GCN
- Justin Horst - OTH
- Michael Schuster - OTH
- Paul Simmons - OTH
- Geraldine Storton - OTH
- Eric Rose - NED
- Philip Facchina - NID
- Donal O'Dwyer - NID
- Michael Spooner - NID
- Shawn Tomasello - NID